Loading
Sleeping cancer cells hide in bone marrow where drugs cannot reach them. Pushing them into the bloodstream on purpose, then treating, might clear them.
Disseminated tumour cells occupy the CXCL12-CXCR4 haematopoietic niche, which shields them from chemotherapy. Plerixafor is an approved CXCR4 antagonist used to mobilise stem cells. A deliberate mobilise-then-treat schedule (plerixafor followed within a day by an antibody-drug conjugate or T-cell engager while cells are in circulation) is testable with agents that already exist.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Dormant cells and minimal residual disease, HR-positive / HER2-negative breast cancer.
Shares Metastasis is understood least and studied last, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.